Olanzapine versus haloperidol in children with autistic disorder: an open pilot study.
about
Use of Atypical Antipsychotics in the Treatment of Autistic DisorderAntipsychotics in the treatment of autismEfficacy and tolerability of pharmacotherapy options for the treatment of irritability in autistic childrenOff-label indications for atypical antipsychotics: A systematic reviewPharmacological interventions for challenging behaviour in children with intellectual disabilities: a systematic review and meta-analysis.The status of pharmacotherapy for autism spectrum disordersTranslational Mouse Models of Autism: Advancing Toward Pharmacological Therapeutics.Haploinsufficiency for Pten and Serotonin transporter cooperatively influences brain size and social behavior.Pharmacological management in children and adolescents with pervasive developmental disorder.Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study.Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders.Developing drugs for core social and communication impairment in autism.Information for physicians and pharmacists about drugs that might cause dry mouth: a study of monographs and published literature.Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome.Systematic review of randomized controlled trials of atypical antipsychotics and selective serotonin reuptake inhibitors for behavioural problems associated with pervasive developmental disorders.Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan.Role of risperidone in children with autism spectrum disorder.Review of antipsychotics in children and adolescents.Comparison between the efficacies of Risperidone with Haloperidol in the treatment of attention-deficit hyperactivity disorder (ADHD) among preschoolers: a randomized double-blind clinical trialAtypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders.Autism spectrum disorders: an overview on diagnosis and treatment.The use of antipsychotics in preschoolers: a veto or a sensible last option?What's in the pipeline? Drugs in development for autism spectrum disorder.Antipsychotics use in children and adolescents: An on-going challenge in clinical practice.The safety of olanzapine in young children: a systematic review and meta-analysis.Asperger's syndrome: diagnosis, comorbidity and therapy.Atypical antipsychotics in the treatment of pathological aggression in children and adolescents: literature review and clinical recommendations.Psychopharmacological interventions in autism spectrum disorder.Olanzapine in the treatment of pervasive developmental disorders: a case series analysisA pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.Atypical antipsychotic medication poisoning: an evidence-based consensus guideline for out-of-hospital management.Pharmacotherapy of emotional and behavioral symptoms associated with autism spectrum disorder in children and adolescents.[Autistic disorder: current psychopharmacological treatments and areas of interest for future developments].Effects of atypical antipsychotic drugs on QT interval in patients with mental disorders.
P2860
Q22241555-2968AEFA-96A1-4E46-A8E6-B09EE70A9B09Q22241891-4BD5DC18-2E99-493C-BD17-8CB6309A2E9CQ24564288-AB9BA00A-0A64-4943-B687-26FEC7E2AA16Q24803302-D922351E-84B2-4468-9856-28BF53F5A133Q26776479-EC335566-47DB-4CFB-A70D-1B7F25E71233Q28239931-6820F313-540B-451A-9A75-DB9BA72932E8Q28394524-D17AE2D2-1937-4ACB-A6F6-D7B976C8CABAQ28508076-43267856-57A6-4118-87B2-33CF6FE542BEQ33521748-751B6C72-2AC3-422E-A427-BC9F28B0370CQ33858314-0E2E53CF-D3EC-4744-8D55-9D6509CA02CCQ34177643-51539358-3B20-447D-8752-EA29C15B10D5Q34822538-383BEF67-83F8-4810-A4ED-2A80A16A0FE3Q35057288-769B424A-1F53-4AD2-986C-70FDF719422DQ35496514-658FC809-48DE-4CBC-8745-D6DF631A2571Q36258557-D66B2839-0A19-41DF-A296-F2CAFF2FD208Q36443014-DBCAD5C8-24F5-4D74-8110-60C61C0C66A8Q36473542-8E1CEAEC-F460-4D85-B981-106608B4FC91Q36613868-3814F309-A103-4FF2-B2EE-211C5B0DEFBDQ37358153-EA1F0876-3AF0-4C60-8166-A198488FAC62Q38095762-348424C4-02D1-407A-9937-9DFA03CB95A0Q38154183-11FB832F-142E-411F-B6B7-0EF5F25C73B3Q38180865-5D8AD78B-5DF0-41A2-BF84-42091176A89BQ38193069-B011379D-5D41-4D7C-97D8-FED837049B07Q38217992-1053684A-5843-48D5-8ACD-71B8F5B86AABQ38242011-D4F011EF-EE36-4E31-AC33-2DE821F1FA6FQ38345718-5BF6C9B5-B7A4-4C14-8E4C-06F7106B8A6BQ38448948-013D4339-1AE2-409F-A984-AE6C1CAE5DE0Q38739577-CC34DE44-981D-4468-9EEC-56571E0BA0D3Q40385595-EE0384B9-B262-46C8-AFA2-0185DC3DBFF0Q44635621-0EED4677-A713-441A-8C38-217BB1042EF0Q46830215-3B9F7AC4-6592-4DCA-99A6-45718633248BQ49332454-4967ED8F-7327-46EC-A978-45B273730823Q50303533-D136093F-B19C-440C-ACCD-465DB3C37BC7Q55074589-6DF63A69-192F-467F-985B-3E83737541B0
P2860
Olanzapine versus haloperidol in children with autistic disorder: an open pilot study.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Olanzapine versus haloperidol in children with autistic disorder: an open pilot study.
@en
Olanzapine versus haloperidol in children with autistic disorder: an open pilot study.
@nl
type
label
Olanzapine versus haloperidol in children with autistic disorder: an open pilot study.
@en
Olanzapine versus haloperidol in children with autistic disorder: an open pilot study.
@nl
prefLabel
Olanzapine versus haloperidol in children with autistic disorder: an open pilot study.
@en
Olanzapine versus haloperidol in children with autistic disorder: an open pilot study.
@nl
P2093
P1476
Olanzapine versus haloperidol in children with autistic disorder: an open pilot study.
@en
P2093
M A Delaney
M S Choudhury
R M Sheikh
R P Malone
P304
P356
10.1097/00004583-200108000-00009
P577
2001-08-01T00:00:00Z